Crossref
use-of-alirocumab-for-the-secondary-prevention-of-cardiovascular-disease-in-a-patient-with-end-stage-renal-disease-on-hemodialysis
Malaysian Journal of Pharmacy · 2021
DOI: 10.52494/cxzk2633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malaysian Journal of Pharmacy, 2021. Verfasst von >Io Chon Vong und 4 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Vong, I. C., Chu, M. F., Évora, M., Chio, W., & Tam, W. C. (2021). use-of-alirocumab-for-the-secondary-prevention-of-cardiovascular-disease-in-a-patient-with-end-stage-renal-disease-on-hemodialysis. Malaysian Journal of Pharmacy. https://doi.org/10.52494/cxzk2633
Vancouver
Vong IC, Chu MF, Évora M, Chio W, Tam WC. use-of-alirocumab-for-the-secondary-prevention-of-cardiovascular-disease-in-a-patient-with-end-stage-renal-disease-on-hemodialysis. Malaysian Journal of Pharmacy. 2021. doi:10.52494/cxzk2633
BibTeX
@article{Vong2021,
author = {Vong, >Io Chon and Chu, >Man Fong and Évora, >Màrio and Chio, >Weng and Tam, >Weng Chio},
title = {use-of-alirocumab-for-the-secondary-prevention-of-cardiovascular-disease-in-a-patient-with-end-stage-renal-disease-on-hemodialysis},
journal = {Malaysian Journal of Pharmacy},
year = {2021},
doi = {10.52494/cxzk2633}
}
EUVIMED